Intellia Therapeutics financials at a glance

+ Portfolio

The revenue of Intellia Therapeutics is reported as 0.03628 billion Dollars in the fiscal year 2023. The earnings were -5.42 Dollars per share in 2023, which was 12.01 higher than 2022. And about -0.40808 billion Dollars are reported as free cash flow in the financials of Intellia Therapeutics 2023. No dividends were paid to the shareholders of the Intellia Therapeutics stock NasdaqGM:NTLA in the financial year 2023.

$36.28M

Revenue

$-5.42

Earnings Per Share

100.00%

Gross Margin %

$-,387.92M

Free Cash Flow

Revenue

36.28

Earnings Per Share

-5.42

Gross Margin %

100.00

Free Cash Flow

-,387.92

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018	2017	2016	2015
Rev.	Revenue	N/A	$36.28M	$52.12M	$33.05M	$57.99M	$43.10M	$30.43M	$26.12M	$16.48M	$0.00M
GM %	Gross Margin %	0.00%	100.00%	0.00%	100.00%	-,159.35%	-,151.52%	-,192.81%	-,159.02%	-93.22%	-84.81%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	-,235.51%	-,246.78%	-,298.58%	-,266.32%	-,195.15%	-,221.86%
EPS	Earnings Per Share	$-5.35	$-5.42	$-6.16	$-3.78	$-2.40	$-2.11	$-1.98	$-1.88	$-1.42	$-51.15
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	0
Sha.	Shares	N/AM	96.11M	88.02M	74.67M	67.73M	50.51M	45.23M	42.39M	36.02M	2.56M
OCF	Operating Cash Flow	N/A	$-,394.09M	$-,333.29M	$-,225.03M	$-49.91M	$-,103.24M	$-61.26M	$-65.28M	$36.11M	$0.00M
FCF	Free Cash Flow	N/A	$-,387.92M	$-,346.85M	$-,237.79M	$-53.50M	$-,110.21M	$-67.62M	$-75.37M	$29.94M	$0.00M
FCFS	Free Cash Flow Per Share	$-4.71	$-4.60	$-5.09	$-3.35	$-0.96	$-2.33	$-1.57	$-2.09	$1.35	$-17.77

Intellia Therapeutics financials at a glance

Financials

Discover